Date: Mar 13, 2019 11:30 AM - 12:30 PM
The Tennessee Pharmacists Consortium for Education is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
- Identify new guideline recommendations for sacubitril/valsartan and iron replacement in heart failure with reduced ejection fraction and discuss the supporting literature
- Outline the most recent guideline-directed treatment recommendations for heart failure with preserved ejection fraction
- Discuss differences in heart rate and blood pressure goals between heart failure with reduced and preserved ejection fraction
- Identify recent literature about the use of digoxin and novel oral anticoagulants in the treatment of atrial fibrillation
- Discuss recent guideline changes and clinical trials which impact the goal blood pressures in patients with hypertension
Zac Cox, PharmD, BCPS
Brief Bio : Dr. Cox attended the University of Tennessee at Chattanooga where he studied pre-pharmacy. He received his Doctor of Pharmacy degree from the University of Tennessee College of Pharmacy in 2008. Since graduation, Dr. Cox has completed a pharmacy practice residency at Vanderbilt University Medical Center focusing on Critical Care and Internal Medicine and holds board certification as a pharmacotherapy specialist (BCPS). Currently, Dr. Cox practices at Vanderbilt University Medical Center on the inpatient Heart Failure specialty team and in Vanderbilt's Program for Inter-professional Learning in a heart failure clinic. His research interests focus on outcomes in heart failure management and the use of inotropic agents in Stage D heart failure.